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The three-dimensional structure of an N-terminal
fragment comprising the first 51 amino acids from hu-
man plasma vitronectin, the somatomedin B (SMB) do-
main, has been determined by two-dimensional NMR
approaches. An average structure was calculated, rep-
resenting the overall fold from a set of 20 minimized
structures. The core residues (18–41) overlay with a root
mean square deviation of 2.29  0.62 Å. The N- and C-
terminal segments exhibit higher root mean square de-
viations, reflecting more flexibility in solution and/or
fewer long-range NOEs for these regions. Residues
26–30 form a unique single-turn -helix, the locus where
plasminogen activator inhibitor type-1 (PAI-1) is bound.
This structure of this helix is highly homologous with
that of a recombinant SMB domain solved in a co-crystal
with PAI-1 (Zhou, A., Huntington, J. A., Pannu, N. S.,
Carrell, R. W., and Read, R. J. (2003) Nat. Struct. Biol. 10,
541–544), although the remainder of the structure dif-
fers. Significantly, the pattern of disulfide cross-links
observed in this material isolated from human plasma is
altogether different from the disulfides proposed for
recombinant forms. The NMR structure reveals the rel-
ative orientation of binding sites for cell surface recep-
tors, including an integrin-binding site at residues 45–
47, which was disordered and did not diffract in the
co-crystal, and a site for the urokinase receptor, which
overlaps with the PAI-1-binding site.
Human vitronectin is a glycoprotein found in the circulation,
where it contributes to hemostasis by regulating blood coagu-
lation and fibrinolysis (1, 2). Vitronectin is also found in the
ECM,1 where it plays important roles in cell adhesion, pericel-
lular proteolysis, tissue invasion, angiogenesis, and metastasis
(3–7). The variety of functions of vitronectin in the two micro-
environments is a manifestation of its ability to interact with
numerous humoral and cellular proteins. An important binding
partner for vitronectin is the serine protease inhibitor PAI-1,
which also is found both in circulation and the ECM. Further-
more, it has different activities depending upon this localiza-
tion; the anti-protease activity of PAI-1 that regulates throm-
bolysis in the circulation is targeted instead toward pericellular
proteolysis when localized to the ECM or cell/matrix boundary.
Vitronectin binds to PAI-1 with high affinity and stabilizes the
inhibitor in its active conformation (8, 9). Vitronectin can also
associate with PAI-1 and assemble to form higher order com-
plexes (10) that exhibit altered adhesive functions (11). Key to
the adhesive functions of vitronectin are its interactions with
cell-surface receptors including integrins and uPAR.
A widely accepted model suggests that vitronectin is orga-
nized into functional domains that provide the broad repertoire
necessary for binding to target ligands (12–14). We recently
used computational methods to predict the structure of the
three domains comprising vitronectin (15). A threading algo-
rithm gave high confidence predictions for the central domain
of 200 amino acids and the C-terminal domain of 100 amino
acids. Both domains exhibit features of a -propeller fold. The
computational approach was less successful for the third do-
main, corresponding to the N-terminal span of 50 amino acids
that has been denoted the “somatomedin B” domain of vitronec-
tin (14). An experimental determination of the fold of this
domain is thus needed and is relevant to over 100 homologues
in the sequence data base. Within this short N-terminal region
from vitronectin lie binding sites for three critical ligands:
PAI-1, integrins, and uPAR. The SMB domain contains eight
cysteine residues that form four disulfide bonds, and recombi-
nant forms of SMB have been used to identify amino acid
residues that participate in binding these ligands (16–19). The
structure of a co-crystal of PAI-1 and a recombinant SMB was
recently reported, further elucidating the features of the bind-
ing interface between vitronectin and PAI-1 (20).
We have purified the SMB domain from human plasma
vitronectin using cyanogen bromide cleavage to release the first
51 amino acids from the bulk of the protein. In this work, two-
dimensional NMR methods have been used to determine the
solution structure of this domain. A single homogeneous species
is observed with a unique disulfide-bonding pattern. Our results
complement the x-ray crystallography on the complex and con-
firm the presence within the SMB domain of a sole -helix con-
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taining known PAI-1-binding residues. However, the remainder
of the chain displays an entirely different fold and different
pattern of disulfides. Furthermore, the NMR structure defines
the position of the integrin-binding tripeptide (RGD) site, which
was unstructured in the co-crystal with PAI-1.
EXPERIMENTAL PROCEDURES
Materials—The C-18 reverse phase HPLC column was obtained from
Vydac, Hesperia, CA. HPLC grade acetonitrile was from Fisher. Cyan-
ogen bromide and trifluoroacetic acid were from Pierce. D2O was from
Cambridge Isotope Laboratories (Andover, MA). All other chemicals
were of the highest purity available.
Cyanogen Bromide Digestion of Vitronectin—Human plasma
vitronectin was isolated as described in Zhuang et al. (21). Purified
vitronectin in an ammonium sulfate suspension was centrifuged at
4000 rpm for 20–30 min at 4 °C. The pellet was resuspended in 0.005%
trifluoroacetic acid and dialyzed against 0.005% trifluoroacetic acid for
4 h at 4 °C. The solvent was removed by lyophilization, and cyanogen
bromide in 70% trifluoroacetic acid containing 200 mM iodoacetamide
was added to the lyophilized vitronectin. The reaction mixture was
flushed with N2 and incubated at room temperature in the dark for
22 h. After 22 h the reaction mixture was diluted with twice the volume
of water and lyophilized. The lyophilized product was resuspended in
1% trifluoroacetic acid and centrifuged. The supernatant was separated
on a 1  25-cm reverse phase C-18 HPLC column by gradient elution
with 17–32% acetonitrile in water containing 0.1% trifluoroacetic acid
to isolate the desired N-terminal fragment representing the SMB do-
main. Fractions were analyzed for purity by re-injecting an aliquot on
the reverse phase C-18 column, and the desired fractions were com-
bined and stored at 20 °C. The size (m/z 5762.3) of the fragment was
confirmed by matrix-assisted laser desorption ionization time-of-flight
mass spectrometry, and its monomeric state was confirmed by sedimen-
tation equilibrium analysis using an Optima XL-I ultracentrifuge from
Beckman. The typical yield of vitronectin was 7–8 mg/liter of human
plasma. The yield of SMB domain was 5%. Four preparations of
vitronectin, each from 2 liters of plasma, were combined to accumulate
the required amount of SMB domain for the NMR experiments.
NMR Spectroscopy—NMR studies were performed with 90 M
SMB in a 500-l sample volume. The lyophilized sample was dissolved
in D2O or H2O containing 10% D2O at the appropriate pH. The sample
pH was adjusted with either 100 mM trifluoroacetic acid or 100 mM
NaOH. All NMR experiments were performed on a 600 MHz Varian
Inova instrument equipped with a single gradient axis and a triple
resonance probe for the observation of proton, carbon, and nitrogen
nuclei. To assign overlapping resonances in two-dimensional NMR
spectra, experiments were recorded at 288, 298, and 308 K and pH
values ranging from 1.4 to 7.3. Best resolution was obtained at pH 4.4,
and all the assignments were reported with respect to the spectra
obtained at pH 4.4 and 298 K. Two-dimensional NMR data were ac-
quired in phase-sensitive mode using the States-Haberkorn (22)
method for quadrature detection in the indirect dimension. Spectra of
SMB in H2O were recorded by using WET (23, 24) or WATERGATE
sequences (25) for water suppression. Two-dimensional homonuclear
NOESY (26) spectra were recorded with mixing times of 150, 200, and
250 ms. TOCSY spectra (27) were recorded using DIPSI spin-lock
sequence with a 8 kHz radio frequency field and mixing times of 15, 30,
60, and 80 ms. Typically, spectra were acquired with 256 t1 increments,
2048 data points, a relaxation delay of 1 s, and a spectral width of 8500
Hz. For DQF-COSY spectra (28), 512 t1 increments were acquired.
Spectra were recorded with 64–96 scans per increment for NOESY,
24–80 scans per increment for TOCSY, and 56 scans per increment for
DQF-COSY. In all NOESY and TOCSY spectra, the data were multi-
plied by a 60–90° phase shifted sin2 window function in both dimen-
sions before Fourier transformation.
Data Analysis and Structure Determination—NMR data were pro-
cessed with Felix 2000 and SPARKY (T. D. Goddard and D. G. Kneller,
The University of California, San Diego) software operating on a Silicon
Graphics Indigo 2 work station or on a Silicon Graphics Origin 300
server. Cross-peak intensities observed in NOE experiments were di-
vided into four categories as strong, medium, weak, and very weak.
These intensities were converted into distance restraints as follows:
strong, 1.8–2.7 Å; medium, 1.8–3.4 Å; weak, 1.8–4.5 Å, and very weak,
1.8–6.0 Å. An additional 1.0 Å was added to upper limits involving
methyl protons. Similarly, an additional 0.5 Å for methylene protons
and 2.3 Å for degenerate H and H protons of tyrosines and pheny-
lalanines were added to the upper limits. Also, 0.2 Å was added to the
upper limits of NOEs involving amide protons. Coupling constants were
extracted from the DQF-COSY spectra. Backbone  angles were re-
strained to 120  50° for 3JHNH  8–9 Hz, and 120  40° for
3JHNH
 9 Hz. A restraint of 100  80° was also applied to the  angle for
residues that show stronger NHi-Hi-1 NOE than the intraresidue
NH-H NOE (29). A total of 329 NOE restraints and 18  restraints
were used in structure determination.
All calculations were carried out using the AMBER force field inter-
faced with DISCOVER (Accelerys, San Diego, CA) on an Origin 300
work station. Random structures were generated by subjecting the
peptide to an initial 10,000-step minimization at 298 K. The tempera-
ture was then raised gradually to 1000 K during a 1000-step dynamics
simulation. The peptide was subjected to minimization and a 10-ps
dynamics run at 1000 K. The NMR-derived restraints were then im-
posed on the peptide and the peptide was slowly annealed to 298 K in
a 100-ps trajectory. Finally, the structures were subjected to further
minimization at 298 K. The force constant for the distance restraints
was 100 kcal/mol Å2 and the dielectric constant was 4. Using this
simulated annealing protocol, an ensemble of 20 starting structures
was obtained. These structures were then used to make further reso-
nance assignments and increase the number of unambiguous NOE
restraints. In the final step of the refinement, 60 structures were
obtained and analyzed by MOLMOL (30) and PROCHECK NMR (31).
The statistics given in Table I are for the 20 structures with the lowest
total energy.
RESULTS
Resonance Assignments—The material used in this study
was the SMB domain isolated from plasma vitronectin, so 1H
NMR was used exclusively because the sample could not be
isotopically labeled. Sequential resonance assignments were
made by the analysis of fingerprint regions of TOCSY and
NOESY spectra using standard procedures (32, 33). Excellent
dispersion was observed in the spectra. Examples that demon-
strate the quality of the data and the dispersion observed in a
one-dimensional spectrum and TOCSY and NOESY spectra are
given in Supplemental Materials Figs. 1–3. There were nu-
merous overlaps, presumably because of the compact and
globular nature of the polypeptide, causing some residues to
be in similar magnetic environments. DQF-COSY was used
to determine 13 unambiguous NH-H coupling constants.
Cross-peaks representing smaller coupling constants were
absent from the DQF-COSY spectrum because of limitations
in concentration of the biological material. All the deter-
mined coupling constants were 8 Hz. There were no pat-
terns of cross-peaks to indicate the presence of regular sec-
ondary structure elements in SMB. Rapid exchange of
virtually all amide protons also supported this observation.
Thus, the backbone assignment strategy relied heavily on the
sequential NOESY-TOCSY cross-peak analyses of the
NH-H regions of the spectra.
Side chain assignments were made on the basis of the scalar
connectivities obtained through a series of TOCSY spectra us-
ing different mixing times at different pH values and temper-
atures. Aromatic parts of tyrosine and phenylalanine residues
were assigned on the basis of NOE cross-peaks. No stereospe-
cific assignments were made for methylene protons. Because of
ring opening of homoserine lactone at higher pH values, a few
residues near the C terminus showed two sets of resonances
with slight differences in chemical shifts that did not hinder
the resonance assignments. A sequential connectivity for the
last three residues was not observed, thus these residues were
tentatively assigned. Residues 9 and 10 were also tentatively
assigned because of resonance overlap. Overall, backbone, and
side chain assignments of 46 residues were completed, suffi-
cient for structural calculations to be performed on this
polypeptide. The single proline residue (Pro41) of SMB was
identified to be in a trans conformation based on the observa-
tion of NOEs between lysine 40 NH/H and proline 41 H. The
complete resonance assignment of SMB is given in Supplemen-
tal Materials Table I.
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Assignment of Disulfides—Attempts to identify the disulfide
bridges from NOE cross-peaks observed between CHi and
CHj and/or between CHi and CHj of cysteines using pub-
lished methods (34, 35) were not successful. Spectral overlap
between intra- and inter-residue NOE cross-peaks involving
cysteines, combined with the spatial proximity of the six cys-
teines in the core region of SMB, precluded unequivocal iden-
tification of the disulfide bridges solely by NMR. Similar prob-
lems have been encountered with other cysteine-rich proteins
(36, 37).
In early stages of simulated annealing calculations, “float-
ing” cysteines were used without any disulfide assignments.
These early structures consistently showed that cysteines 5
and 9 were near each other, and four cysteines (Cys19, Cys21,
Cys31, and Cys32) formed a cluster in the core of SMB. Either
cysteine 25 or cysteine 39 was also near this cluster in most
structures. In a concurrent study from this laboratory, two of
the disulfide bonds of SMB were determined by biochemical
methods and mass spectrometry.2 This work revealed one di-
sulfide bridge as 5–9 and another as 25–39. These findings
were in agreement with the initial calculations, so the two
experimentally determined disulfides were imposed to refine
the structure of the SMB domain, and two possible alternatives
were then pursued separately in the structure determination.
These alternatives were: SMB with Cys19–Cys31 and Cys21–
Cys32 disulfides or SMB with Cys19–Cys32 and Cys21–Cys31
disulfides. A third alternative pairing among the four cysteines
is not feasible and was not considered because it would involve
a disulfide bridge between adjacent cysteines 31 and 32. The
disulfide bridge restraints were set for the two alternatives
(38), and both were subjected to simulated annealing sepa-
rately. Calculations with the second alternative involving di-
sulfides 19–32 and 21–31 did not yield acceptable converged
structures. Thus, the structure of SMB containing disulfides
5–9, 19–31, 21–32, and 25–39 was determined and is described
in this work.
Structure Refinement—The three-dimensional structure of
SMB was determined by simulated annealing calculations us-
ing a total of 347 NMR-determined restraints (Table I). A large
fraction of intra- and intermolecular NOEs were observed in
the region spanning residues 18–41 of SMB. It should be noted
that NOEs involving any tentatively assigned residues (Sup-
plemental Materials Table I) were not included in structure
calculations. As described above, the best structures from ini-
tial calculations were selected and used as starting structures
with imposed disulfide restraints (Cys5–Cys9 and Cys25–Cys39)
for the final stages of the structure calculation. The 20 lowest
energy structures were chosen from among an ensemble of 60
minimized structures. The Ramachandran plot showed that
90% of  and  angles were within the most favored and
allowed regions, and less than 7% of the  and  angles from
all 20 structures were within the disallowed region. Cluster
analysis resulted in a r.m.s. deviation value for the backbone
atoms of the 20 structures of 2.29  0.62 Å when the region
limited to residues 18–41 was considered (Fig. 1a). The low
r.m.s. deviation for this portion of the structure resulted be-
cause the majority of the observed NOEs were from the resi-
dues in this region, which also contains three of the four disul-
fide bridges that stabilize the compact structural core of the
domain.
Fig. 1b shows the entire chain trace for all 20 resulting
structures superimposed in this region spanning residues 18–
41. These data indicate that, in solution, the core region of SMB
yields converged structures, whereas the structures at both the
N- and C-terminal ends of the molecule are less well defined.
The greater flexibility of the C-terminal region (residues 42–
51) compared with the core is apparent from the NMR data,
which showed sharper resonances and chemical shifts similar
to random coil values for these residues (Fig. 2). Another in-
teresting feature of the structure is the lower refinement of the
N-terminal section, which contains the fourth disulfide bridge
2 Horn, N. A., Hurst, G. B., Mayasundari, A., Whittemore, N. A.,
Serpersu, E. H., and Peterson, C. B. (2004) J. Biol. Chem., in press.
TABLE I
Summary of statistics for the family of 20 SMB structures
NOE upper distance limits 329
Intra-residue 226
Sequential (i, i  1) 81
Medium-range (i, i  2 to 3) 17
Long-range (i, i   4) 5
Dihedral angle constraints (, , and 	) 18
Residual NOE violationsa
Number  0.5 Å 7  2b
Number  0.8 Å 3  1
Residual angle violationsa
Number 10° 5  2b
Number 30° 2  1
Mean r.m.s. deviation (Å)c
Residues 1–51 6.72  1.38
Residues 18–41 (core) 2.29  0.62
Procheck-NMR version 3.5.4 output (residues 1–51) Ensemble of 20 structures Average structurec
Ramachandran plot statistics
Residues in most favored regions (A, B, L) 452 (50.2%) 22 (51.2%)
Residues in additional allowed regions (a, b, l, p) 339 (37.7%) 15 (34.9%)
Residues in generously allowed regions (a, b, l, p) 51 (5.7%) 2 (4.7%)
Residues in disallowed regions 58 (6.4%) 4 (9.3%)
Total number of non-glycine and non-proline residues 900 (100.0%) 43 (100.0%)
Other statistics (standard deviation in degrees)
H-bond energy 0.6 0.7
Chi-1 “pooled” 12.8 15.8
Chi-2 trans 17.0 18.6
a The NMR_refine module within InsightII 2002 (Accelrys, San Diego, CA) was used to determine the NOE and dihedral angle violations.
b This number represents the number of violations among all 20 structures. Significantly, no single restraint was violated by the majority of
structures.
c MOLMOL (28) was used to determine this structure.
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between cysteines 5 and 9. Despite all efforts, no unambiguous
NOEs could be identified between this section and the core
region to define its relative orientation. This is perhaps not
surprising because global bends can be difficult to detect by
NMR, as long-range NOEs do not exist. Also, the higher r.m.s.
deviation for this region of the SMB domain may result from
inherent limits in sensitivity that arise from the low concen-
tration of this sample isolated from human plasma, precluding
observation of weaker NOEs. Also, there are relatively few
unambiguous intra-domain NOEs. On the other hand, the less
refined structure may indicate that this region is more flexible
than the core region in solution. The lack of interaction of the
4 H protons of cysteines 5 and 9, combined with the ambiguity
of the resonance assignments of cysteine 9, is consistent with
these observations and suggests that the corresponding disul-
fide bridge is either somewhat flexible or located in a more
mobile part of the molecule.
Solution Structure of the Somatomedin B Domain of
Vitronectin—The average structure, shown in Fig. 1c, yields an
r.m.s. deviation value of 2.29 Å for the core backbone atoms of
the ensemble. As shown in this figure, the core region of SMB
is held by three disulfide bridges, which form the disulfide
knot. The only regular secondary structure is a single-turn
-helix spanning residues 26–30. Observation of successive
dNN(i,i	1) NOEs (see Supplemental Materials Fig. 4), a single
dNN(i,i	3) NOE, and up-field shifted H resonances of residues
26–30 (Fig. 2) also support the presence of a short -helix in
this region. A second region that has a loosely defined 310 helix
spans residues 36–38. The remainder of the molecule is com-
prised of loops, some of which appear to be flexible in solution.
Rapidly exchanging amide protons and the lack of strong
dN(i,i	1) NOEs are consistent with the absence of -sheet in
the rest of the molecule. Hydrogen-deuterium exchange studies
of the SMB domain showed that virtually all of the backbone
amide and other exchangeable protons of the molecule were
exchanged within a few minutes of exposure to D2O, indicating
that the majority of the residues of SMB are exposed to solvent
and signifying the absence of a hydrogen-bonded network of
protons in the molecule. This observation is in accord with the
determined solution structure of SMB, in which the N- and
FIG. 1. Solution structure of the SMB domain determined by NMR. An overlay of the backbone in the core region (residues 18–41) from
the 20 lowest energy structures calculated from the two-dimensional 1H NMR data is shown in panel a. A backbone overlay of these 20 structures
for the entire length of the SMB domain is shown in panel b, with the core region in blue, the N-terminal residues (1–17) in red, and the C-terminal
residues (42–51) in green. The r.m.s. deviation for backbone residues in the core region (panel A) is 2.29  0.62 Å, and the r.m.s. deviation for all
the residues (1–51, panel B) is higher (6.72  1.38 Å), reflecting the mobility of the N- and C-terminal regions in solution. The average structure
calculated from the 20 lowest energy structures is shown in the ribbon structure for the main chain in panel c. The four disulfide connections are
shown in yellow, and the single-turn -helix is highlighted in green. The side chains for the integrin-binding tripeptide (RGD) sequence are shown,
along with the van der Waals surface associated with this binding site.
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C-terminal segments are flexible with a small, solvent-accessi-
ble core that is stabilized by three disulfide bonds.
DISCUSSION
A crystal structure of a complex between PAI-1 and a recom-
binant 51-residue SMB domain has been published recently
(20), with an ordered structure observed only for residues 3 to
39 of the domain. The x-ray structure does not superimpose
well with the solution structure calculated from the NMR data,
either as the entire structure from residues 3 to 39 (Fig. 3A,
r.m.s. deviation  8.3  0.6 Å for backbone atoms) or within the
more highly refined core region defined by residues 18 to 39
(r.m.s. deviation  6.3  0.4 Å for backbone atoms). Further-
more, the assignments of disulfide bridges are altogether dif-
ferent in the two structures. The disulfide pattern of the do-
main used in crystallography also differs from a third disulfide
pattern determined with another recombinant form of the SMB
domain (39). The inconsistencies may stem from difficulties
involved in expressing fragments of proteins with multiple
disulfide bonds by recombinant technology, amounting to over
100 possibilities for the set of 8 cysteine residues. Significantly,
there is no evidence for disulfide “scrambling” in the SMB
domain derived from plasma vitronectin, as a homogeneous
species with a unique disulfide-bonded structure was obtained
from multiple preparations using cyanogen bromide digestion.
This contrasts with the production of a mixture of folds from
expression of the recombinant SMB protein, with only a frac-
tion that is active in binding PAI-1 (39).
Because of the inherent difficulties associated with expres-
sion of cystine-rich sequences in prokaryotes, which lack the
necessary post-translational machinery to incorporate disul-
fide bonds in an analogous way to higher eukaryotes, the strat-
egy for this work mandated purification of this domain from
full-length vitronectin that, in turn, was isolated from natural
sources. It was reasoned that an unambiguous assignment of
the disulfides in the SMB domain from human circulatory
vitronectin was required as a “standard” by which the recom-
binant surrogates must be measured. Neither of the recombi-
nant SMB domains exhibits the same pattern of the 4 cystines
observed for the human plasma counterpart; the only common
disulfide comparing the SMB structure in this work with the
two recombinant forms is the bond between cysteines 5 and 9,
which is also observed in the form of SMB characterized by the
Loskutoff laboratory (39). A puzzling result is that both recom-
binant forms of the SMB domain bind to PAI-1. Could these
results imply that the particular disulfide order is not critical
for the function of this domain, as long as a compact structure
with properly oriented residues for ligand binding is mani-
fested? Inspection of the structural features of this domain, as
follows, is needed to further consider this question.
Although the assignments of the disulfide bridges are com-
pletely different between the recombinant SMB domain used in
crystallography and the SMB domain prepared from plasma
vitronectin, there are notable similarities between the two
structures. Both structures show a single-turn -helix involv-
ing residues 26–30 (Fig. 3A). Superpositioning of the crystal
structure and NMR structure in this region yields 1.09 Å r.m.s.
deviation. Also, a single-turn 310 helix identified in the crystal
structure is also observed in the solution structure, and super-
positioning of this region (residues 36–38) yields a r.m.s. devi-
ation of 0.88 Å. Indeed, these are the only secondary structural
FIG. 2. Differences in chemical shifts for -protons in SMB
relative to standard values for free amino acids. Up-field shifts
are shown below the line, and downfield shifts above the line. The two
clusters of up-field shifts correspond to the two secondary structural
elements, the -helix from 26 to 30 and the 310 helix from 36 to 38.
FIG. 3. Comparison of SMB structures from 1H NMR and x-ray
crystallography. Panel A shows an overlay of the solution structure
(blue) and crystal structure (red) for residues 3–39, the ordered region
that gave a diffraction pattern in the crystallography work (Ref. 18,
Protein Data Bank accession code 1OC0). The structures were aligned
by overlaying the single -helix, shown in yellow for both structures,
with an r.m.s. deviation of 1.09 Å. The 310 helix is shown in green for
both structures. Panel B shows the relative orientation of PAI-1-binding
residues in the solution structure (blue) and x-ray structure (red).
Residues identified to participate in PAI-1 binding by site-directed
mutagenesis (17) are shown by side chains for Asp22, Leu24, Tyr27,
Tyr28, and Asp34, and by highlighting the backbone region for Gly12.
Three additional residues, Thr10, Phe13, and Glu23, were identified at
the PAI-1-binding interface from the crystallography work (20). Labels
are shown in violet for residues that occupy overlapping positions, and
labels are shown in black for residues with different orientations in the
two structures. Hydrogen positions were not determined in the co-
crystal (20) and are shown for the NMR structure only.
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elements in either of the structures, and the rest of the SMB
domain shows no regular secondary structure elements from
NMR or x-ray crystallography analysis. Although these two
secondary structural features are nearly identical, their rela-
tive orientation in the two structures differs (Fig. 3A).
The single -helix is found within a fairly large loop defined
by the disulfide pair, Cys25–Cys39. This structure is in many
ways reminiscent of a subclass of cystine knot structures clas-
sified as cystine-stabilized -helices (CSH motifs (40, 41)), al-
though there are differences in the sequence positions of indi-
vidual cysteines in the SMB domain relative to the helix
compared with prototypical CSH motifs. Such structures are
known to function in binding extracellular ligands (41). Despite
different disulfide bonding in the core, the plasma-derived and
recombinant versions of SMB fold with a single helix analogous
to the CSH motif. In the large family of CSH domains, it is
observed that a variety of disulfide-bonding patterns can be
tolerated within the core of the domain, providing a structural
scaffold that orients the -helix on the surface (41). Thus, the
curious retention of PAI-1 binding among this set of clearly
different folds for the SMB domain is consistent with the dem-
onstrated malleability of cystine knot structures to accommo-
date cysteine substitutions, yet retain activity (41–45). Even
though the recombinant forms of the SMB domain do not have
the correct cystine bonds found in circulating vitronectin, PAI-1
binding appears to be maintained because the various disulfide
cross-linked frameworks support the formation of the sole -he-
lix in this domain.
The single conserved -helix houses two of the residues,
Tyr27 and Tyr28, which were identified from site-directed mu-
tagenesis studies (17) to participate in binding to PAI-1, with
two others (Asp22 and Leu24) present in a turn that immedi-
ately precedes this helix. Fig. 3B shows the relative positioning
in the NMR and crystal structures of these and other side
chains that have been implicated as important for PAI-1 bind-
ing to vitronectin. As shown in the figure, five residues previ-
ously identified to participate in PAI-1 binding (Thr10, Glu23,
Leu24, Tyr27, and Tyr28) occupy the same positions. Differences
are observed for the relative orientation of Gly12, Phe13, Asp22,
and Asp34 in the two structures. As shown in more detail in the
space-filling representation of the SMB domain presented in
Fig. 4A, these residues appear to form a PAI-1-binding surface
that encompasses two contiguous regions; the first region in-
cludes Gly12, Phe13, and Thr10, and the second contains Asp22,
Glu23, Leu24, Tyr27, and Tyr28. The first set of residues lies
within the N-terminal region containing the Cys5–Cys9 disul-
fide, whereas the second group is found in the vicinity of the
-helix. As discussed above, this helix lies within the more
structured SMB core that is stabilized by the other three dis-
ulfides (Cys19–Cys31, Cys21–Cys32, and Cys25–Cys39). Thr10
and Phe13 are positioned further apart in the x-ray structure
(Fig. 3B), and Gly12 is not found within the binding surface
identified in the co-crystal. Asp34 is remote from the PAI-1-
binding interface in both the NMR and crystal structures.
An overlay was constructed with the SMB domain deter-
mined by NMR in place of the SMB domain observed in the
co-crystal to test whether this putative binding surface com-
prises the functional PAI-1-binding site in this region of
vitronectin. These results are shown in Fig. 4B. The intimate
association of the SMB domain with PAI-1 is apparent from
this figure, which highlights PAI-1-binding residues within the
SMB domain in turquoise, as well as residues in PAI-1 that are
known to be important for vitronectin binding (8) shown in
blue. Clearly, this surface containing Thr10, Glu12, Phe13,
Asp22, Glu23, Leu24, Tyr27, and Tyr28 is the binding site for
PAI-1. Measured distances between backbone atoms (all less
than 8 Å between -carbons) from the SMB domain to PAI-1 in
the overlaid structure suggest that the region from Thr10 to
Phe13 in the SMB domain contacts Phe109, Met110, and Leu116
in PAI-1, three residues proposed to interact with vitronectin
FIG. 4. Features of the SMB domain involved in PAI-1 binding. Panel A shows a ribbon trace of the backbone of the SMB domain with CPK
surfaces for residues that are proposed to interact with PAI-1 from prior mutagenesis work (17) and the co-crystal with PAI-1 (20). These include
Thr10, Gly12, Phe13, Asp22, Glu23, Leu24, Tyr27, and Tyr28, shown by labels in the figure. Disulfide bonds within the SMB domain are shown in
yellow. Panel B presents the structure for the SMB domain determined by NMR superimposed on the structure from the co-crystal of recombinant
SMB and PAI-1 (20). The SMB domain was positioned in the structure by overlaying the -helix (residues 26–30) that is coincident in the NMR
structure and the crystal structure; only the NMR structure is shown for the SMB domain to depict the positions of the proposed residues at the
PAI-1/SMB interface. The SMB domain is presented in the turquoise ribbon structure with turquoise CPK surfaces for the residues (highlighted
in panel A) that have been implicated as important for PAI-1 binding from previous work on the SMB domain (17, 20). The RGD integrin-binding
motif is highlighted in green CPK structures. PAI-1 is shown by the gray strand, depicting -sheets with yellow ribbons, and -helices as red
cylinders. The central -sheet (A sheet) and reactive center loop (RCL) of PAI-1 are labeled, as well as the F helix that appears to form numerous
contacts with the SMB domain. Residues that have been identified as important for vitronectin binding in site-directed mutagenesis studies on
PAI-1 ((8) Phe109, Met110, Leu116, and Gln123) are featured in the blue CPK structures.
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(8). Likewise, the region in the vicinity of the -helix encom-
passing Asp22 to Tyr28 interacts with Gln125 in PAI-1, another
residue that is critical for binding vitronectin (8). Extensive
interactions from the second group of residues (near the helix
within the stable core of the SMB domain) also are observed
with helix F in PAI-1. Taken together, these results agree with
mutagenesis work, combined with protection of PAI-1 against
chemical inactivation, that has localized the vitronectin-bind-
ing site in PAI-1 to the region spanning helix F, -strand 2A,
and helix E in PAI-1 (46–48).
From this analysis, it appears that vitronectin stabilizes
PAI-1 via this interface in the SMB domain, which binds across
the E and F helices of PAI-1, preventing the movement of
strands 1 and 2 of the main -sheet in PAI-1 that occurs in the
relaxation of PAI-1 to a latent form (20). As described above,
this -helix in the SMB domain is highly homologous between
the two structures (Fig. 3A), although the remainder of the
structure, including the 310 helix region, does not overlap.
Theoretically, it is possible that changes in the fold of the
domain occur upon binding to PAI-1, and these could account
for some of the differences in the structure of the domain
comparing results from NMR and crystallography. However,
the overlaid structures do not support such changes because
the interface for PAI-1 binding appears to be fully formed and
extensive in the NMR structure without PAI-1 present.
The SMB domain is key to many of the varied functions of
vitronectin because it contains binding sites not only for PAI-1,
but also for cell surface receptors, uPAR, and integrins. The
orchestration of vitronectin binding to PAI-1 and these recep-
tors modulates fibrinolysis and cell migration. The binding of
PAI-1 appears to block interaction with uPAR (19). Alanine-
scanning mutagenesis (19) has shown that residues involved in
uPAR binding virtually overlap with important PAI-1-binding
residues in the region of the -helix: Asp22, Glu23, Leu24, Tyr27,
and Tyr28 (Fig. 3B). The binding site for integrins is the RGD
sequence comprising residues 45–47 in the SMB domain,
shown in the van der Waals surface in Fig. 1C. This sequence
lies within the C-terminal portion of the SMB domain, in a
region that exhibits more flexibility than the core containing
residues 18–41 (Fig. 1). The RGD sequence was disordered in
the co-crystal structure with PAI-1, so insight into the relative
orientation of the RGD sequence and the PAI-1-binding site is
provided for the first time from the solution structure. As
shown in the space-filling model in Fig. 4B, the RGD sequence
is clearly separate from the PAI-1-binding surfaces in this
small domain.
The demonstrated flexibility of this region may be relevant to
ongoing work needed to clarify conflicting results regarding
PAI-1 effects on vitronectin activity in vitro and in vivo (49–
56). It is usually accepted that PAI-1 and integrin binding are
mutually exclusive because of the proximity of the two binding
sites within the compact SMB domain (20). To the extent that
these two ligand-binding regions are located close to each other
on the SMB domain, the solution structure supports this idea.
However, the binding sites are clearly separate and will not
necessarily be mutually exclusive in their binding functions. In
this regard, we previously have observed that PAI-1 binds to
vitronectin and promotes the assembly of higher-order com-
plexes that become preferentially associated with the ECM, are
internalized and degraded together in cell culture, and actually
bind integrins more avidly (11). The relative disorder within
this C-terminal region of the SMB domain housing the RGD
sequence, combined with a closely spaced, but separate binding
site for PAI-1, suggests that there may be scenarios that can
accommodate simultaneous binding of PAI-1 and integrins.
Indeed, the flexibility of this region may contribute to modu-
lating affinity of PAI-1 for vitronectin, ultimately influencing
the role of PAI-1 in regulating cellular adhesion and migration.
The role in adhesion and matrix organization is one of the
most compelling areas of research on vitronectin. There is a
close interplay between uPAR, integrins, vitronectin, and
PAI-1 in regulating cell invasiveness. Multiple lines of evidence
exist for association of uPAR with integrins to coordinate the
effects of the two classes of receptors in mediating signaling
and promoting cellular rearrangement and/or migration (57–
65). This new information defining the relative location of
binding sites for PAI-1 and the two receptors within the SMB
domain will be invaluable for considering mechanisms by
which these receptors and the ECM communicate in a recipro-
cal manner, ultimately with the goal of developing new anti-
tumor and anti-thrombotic agents.
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